血浆基质金属蛋白酶8升高与肺结核痰培养阳性相关
该研究评估血浆基质金属蛋白酶(MMP)及III型前胶原氨基端前肽在结核治疗前后的浓度作为生物标志物。血浆MMP-1、MMP-8和MMP-10浓度在治疗期间显著下降。血浆MMP-8在痰结核分枝杆菌培养阳性者中较培养阴性者升高,治疗前中位数4993 pg/mL vs 698 pg/mL(P=0.004),治疗6个月后3650 pg/mL vs 720 pg/mL(P=0.008)。
要点
- 血浆MMP-1、MMP-8、MMP-10浓度在结核治疗期间显著下降。
- 治疗前痰培养阳性者血浆MMP-8中位数4993 pg/mL,阴性者698 pg/mL(P=0.004)。
- 治疗6个月后痰培养阳性者血浆MMP-8中位数3650 pg/mL,阴性者720 pg/mL(P=0.008)。
核心结论
- 血浆MMP-8是增强结核治疗监测和筛查可能培养阳性的潜在生物标志物。
研究设计与样本
- 评估血浆MMP及III型前胶原氨基端前肽浓度在结核治疗前和治疗期间作为生物标志物的研究。
主要发现
- 血浆MMP-1、MMP-8和MMP-10浓度在治疗期间显著下降。
- 治疗前痰培养阳性者血浆MMP-8中位数4993 pg/mL(四分位距2542-9188),培养阴性者698 pg/mL(218-4060),P=0.004。
- 治疗6个月后痰培养阳性者血浆MMP-8中位数3650 pg/mL(1214-3888),培养阴性者720 pg/mL(551-1321),P=0.008。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current methods for tuberculosis treatment monitoring are suboptimal. We evaluated plasma matrix metalloproteinase (MMP) and procollagen III N-terminal propeptide concentrations before and during tuberculosis treatment as biomarkers. Plasma MMP-1, MMP-8, and MMP-10 concentrations significantly decreased during treatment. Plasma MMP-8 was increased in sputum Mycobacterium tuberculosis culture-positive relative to culture-negative participants, before (median, 4993 pg/mL [interquartile range, 2542-9188] vs 698 [218-4060] pg/mL, respectively; P = .004) and after (3650 [1214-3888] vs 720 [551-1321] pg/mL; P = .008) 6 months of tuberculosis treatment. Consequently, plasma MMP-8 is a potential biomarker to enhance tuberculosis treatment monitoring and screen for possible culture positivity.
引用
- Walker NF, Karim F, Moosa MYS, et al. Elevated Plasma Matrix Metalloproteinase 8 Associates With Sputum Culture Positivity in Pulmonary Tuberculosis. J Infect Dis. 2022. PMID: 35510939. doi:10.1093/infdis/jiac160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。